Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:17:50 EDT Tue 21 Mar 2023
Enter Symbol
or Name
USA
CA



News for U:CADL from 2022-03-22 to 2023-03-21 - 20 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-02-01 08:00U:CADLNews ReleaseCandel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
2023-01-12 08:00U:CADLNews ReleaseCandel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
2022-12-06 16:27U:CADLNews ReleaseCandel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
2022-11-29 08:00U:CADLNews ReleaseCandel Therapeutics to Host Virtual R&D Day on December 6, 2022
2022-11-18 08:00U:CADLNews ReleaseCandel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
2022-11-11 12:00U:CADLNews ReleaseCandel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
2022-11-10 08:00U:CADLNews ReleaseCandel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
2022-11-07 08:00U:CADLNews ReleaseCandel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
2022-11-01 08:00U:CADLNews ReleaseCandel Therapeutics Upcoming Investor Conference Participation for November
2022-10-26 08:00U:CADLNews ReleaseCandel Therapeutics Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
2022-09-15 08:00U:CADLNews ReleaseCandel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
2022-09-07 08:00U:CADLNews ReleaseCandel Therapeutics Announces Two Executive Leadership Appointments
2022-09-06 08:00U:CADLNews ReleaseCandel Therapeutics Upcoming Investor Conference Participation
2022-08-05 08:00U:CADLNews ReleaseCandel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
2022-08-01 08:00U:CADLNews ReleaseCandel Therapeutics Appoints Three New Members to its Board of Directors
2022-05-26 17:30U:CADLNews ReleaseCandel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
2022-05-18 08:00U:CADLNews ReleaseCandel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
2022-05-12 08:00U:CADLNews ReleaseCandel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
2022-04-27 16:00U:CADLNews ReleaseCandel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-03-29 08:00U:CADLNews ReleaseCandel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights